Fennec Pharmaceuticals (FENC) Tops Q4 EPS by 7c

Fennec Pharmaceuticals (NASDAQ: FENC) reported Q4 EPS of ($0.06), $0.07 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $7.92 million versus the consensus estimate of $7.88 million.

For earnings history and earnings-related data on Fennec Pharmaceuticals (FENC) click here.

You May Also Be Interested In

• PepsiCo (PEP) Misses Q2 EPS by 1c, Beats on Revenue
• Stifel: 'We expect IONS shares to trade lower today and ALNY shares to be volatile'
• BofA Securities Downgrades Goldman Sachs BDC, Inc. (GSBD) to Underperform